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Abstract: Atypic lipomatous tumors (ALT) and dedifferentiated liposarcomas (DDLS) are closely re-
lated liposarcoma subtypes, often difficult to distinguish but they exhibit an entirely different clinical
outcome. Recently discovered regulatory functions of miRNAs in liposarcoma progression prompted us
to investigate miRNAs as potential diagnostic biomarkers in liposarcoma with a main focus on circulat-
ing miRNAs for fast and reliable differential diagnosis. Tumor and blood samples of 35 patients with
lipomatous lesions collected between June 2011 and September 2014 were analyzed by qRT-PCR. They
included 10 lipomas, 7 ALT, 5 DDLS and 13 myxoid liposarcomas (MLS). Ten samples of normal fat
tissue and blood from 20 healthy volunteers were used as controls. A meta-analysis of public data on
miRNA expression in liposarcoma revealed 9 miRNAs with potential diagnostic power. Out of these,
miRNA-155 was found significantly elevated in the circulation of DDLS patients as compared to the
plasma levels detected in all other liposarcoma subtypes and in healthy subjects. miRNA-155 levels in
the plasma samples correlated significantly (r=0.41, p=0.02) with those in corresponding tumor extracts.
This correlation was even more pronounced in an analysis of plasma and tumor extracts of malignant
liposarcoma subtypes alone (r=0.51, p=0.02). Receiver operating characteristic analysis indicated that
plasma miRNA-155 levels have a high diagnostic accuracy for distinguishing DDLS from healthy subjects
(AUC=0.91, p=0.005) and from lipomas (AUC=0.86, p=0.02), MLS (AUC=0.92, p=0.006) and most
importantly ALT (AUC=0.91, p=0.01) patients. In conclusion, this study identified miRNA-155 as a
first blood biomarker for the differential diagnosis of DDLS.
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Abstract: Atypic lipomatous tumors (ALT) and dedifferentiated liposarcomas (DDLS) are closely related liposarcoma 
subtypes, often difficult to distinguish but they exhibit an entirely different clinical outcome. Recently discovered 
regulatory functions of miRNAs in liposarcoma progression prompted us to investigate miRNAs as potential diagnos-
tic biomarkers in liposarcoma with a main focus on circulating miRNAs for fast and reliable differential diagnosis. 
Tumor and blood samples of 35 patients with lipomatous lesions collected between June 2011 and September 
2014 were analyzed by qRT-PCR. They included 10 lipomas, 7 ALT, 5 DDLS and 13 myxoid liposarcomas (MLS). 
Ten samples of normal fat tissue and blood from 20 healthy volunteers were used as controls. A meta-analysis of 
public data on miRNA expression in liposarcoma revealed 9 miRNAs with potential diagnostic power. Out of these, 
miRNA-155 was found significantly elevated in the circulation of DDLS patients as compared to the plasma levels 
detected in all other liposarcoma subtypes and in healthy subjects. miRNA-155 levels in the plasma samples cor-
related significantly (r=0.41, p=0.02) with those in corresponding tumor extracts. This correlation was even more 
pronounced in an analysis of plasma and tumor extracts of malignant liposarcoma subtypes alone (r=0.51, p=0.02). 
Receiver operating characteristic analysis indicated that plasma miRNA-155 levels have a high diagnostic accuracy 
for distinguishing DDLS from healthy subjects (AUC=0.91, p=0.005) and from lipomas (AUC=0.86, p=0.02), MLS 
(AUC=0.92, p=0.006) and most importantly ALT (AUC=0.91, p=0.01) patients. In conclusion, this study identified 
miRNA-155 as a first blood biomarker for the differential diagnosis of DDLS. 
Keywords: Liposarcoma, miRNA, plasma biomarker, diagnostic biomarker
Introduction
Liposarcomas (LS) are a heterogeneous group 
of adipocytic tumors that represent approxi-
mately 13% of all sarcomas [1-3]. The WHO 
classification distinguishes four histologically 
distinct LS subtypes: atypic lipomatous tumors 
(ALT) (synonymously well differentiated liposar-
coma, WDLS), dedifferentiated liposarcomas 
(DDLS), myxoid liposarcomas (MLS) and pleo-
morphic liposarcomas (PLS) [4]. 
Atypic lipomatous tumors represent more than 
40% of all LS and the most frequent LS sub-
type. They are low grade, locally aggressive and 
clinically often difficult to distinguish from 
benign lipomas. Karyotypically, ALT are charac-
terized by supernumerary rings and giant chro-
mosomes, which involve amplification of the 
12q13-15 chromosomal region, containing the 
oncogenes MDM2 and CDK4 [5, 6]. However, 
ALT can undergo dedifferentiation, particularly 
those located in the retro-peritoneum, and turn 
into high grade tumors with high metastatic 
potential. These tumors, defined as DDLS, are 
much more aggressive and, consequently, the 
patients have a much worse prognosis and an 
almost 3-fold higher mortality than those with 
ALT [7, 8]. Karyotypic rearrangements in DDLS 
and ALT result in the expression of MDM2 and 
CDK4 that are used as important immunohisto-
chemical markers to distinguish these two LS 
subtypes from lipomas or pleomorphic LS. 
Myxoid liposarcoma is the second most fre-
quent LS subtype and, if its histology does not 
show round cell components, it is a low grade 
tumor that rarely metastasizes. However, along 
the progression of the disease, accumulation 
of round cell components indicates a more 
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aggressive high grade tumor phenotype and is 
therefore a crucial prognostic marker [9]. In 
more than 95% of all MLS cases a reciprocal 
chromosomal translocation t(12;16)(q13;p11) 
is observed, which results in the expression of 
a FUS-CHOP aberrant transcription factor that 
influences adipocyte differentiation and stimu-
lates adipocytic proliferation and tumorigene-
sis [10-12]. 
Pleomorphic LS is a high grade sarcoma and 
the least frequent of all LS subtypes. It is often 
difficult to distinguish from other pleomorphic 
sarcomas [13]. It is characterized by complex 
chromosomal rearrangements and a very 
aggressive phenotype [14].
Considering the differences in clinical outcome 
of the different LS subtypes, the exact classifi-
cation is of the utmost importance for the clini-
cian when decisions on the treatment of indi-
vidual patients need to be made. Even with 
multimodal treatment including surgery, radia-
tion and chemotherapy, high rates of recur-
rence and of metastasis in LS patients result in 
an overall survival of only 50% [15]. However, 
the differences in treatment success between 
LS subtypes are quite considerable. MLS are 
more sensitive to chemo- and radiotherapy 
than other LS subtypes, and the sensitivity of 
different tumor types drops with dedifferentia-
tion [15]. Up to now, careful histology and tumor 
grading based on the degree of dedifferentia-
tion remain the best prognostic indicators. 
Accordingly, DDLS is a high grade tumor with 
high rates of recurrence and metastasis com-
pared to its low grade well differentiated coun-
terpart ALT. DDLS exhibits a short median pro-
gression free survival of only 2 months when 
compared to 11 months observed for ALT [15]. 
With such clear differences in prognosis for dif-
ferent LS subtypes, an accurate diagnosis is of 
great importance. Unfortunately, common 
genetic rearrangements observed in ALT and 
DDLS and the lack of suitable specific diagnos-
tic markers for the two LS subtypes require 
extensive and laborious histopathological anal-
yses including IHC, FISH, CGH and qRT-PCR for 
a meaningful diagnosis. Consequently, there is 
a need for novel, preferably non-invasive diag-
nostic markers that will facilitate the diagnostic 
procedures. Interestingly, in LS, unlike in many 
other cancer types, neither diagnostic nor prog-
nostic noninvasive biomarkers have so far been 
reported.
A recently rapidly growing volume of data indi-
cates that small non coding RNAs (miRNAs) are 
useful biomarkers for both, a biological as well 
as a clinical characterization of tumors. miR-
NAs mainly target 3’-UTRs of mRNAs and there-
by repress target gene expression [16]. In sar-
comas, miRNA profiling in tumor tissue so far 
proved to be useful for tumor subtype classifi-
cation, as well as for the assessment of aggres-
siveness, response to therapy and differentia-
tion [17, 18]. Importantly, miRNAs have been 
shown to be remarkably stable in blood, mak-
ing them suitable non-invasive biomarkers. The 
biology of miRNAs in LS is not well explored 
and, so far, only a few studies reporting miRNA 
expression in LS have been published [18-22]. 
In these studies, a comparison between miRNA 
expression profiles in tumor tissue of different 
LS subtypes and in normal fat tissue estab-
lished distinct subtype specific miRNA signa-
tures and, in some studies, the biological role 
of certain miRNAs was further investigated [20-
22]. However, there are considerable differenc-
es between the results presented in these 
studies. A minimal overlap of miRNA expression 
profiles reported in these studies for distinct LS 
subtypes asks for additional validation studies. 
Finally, to our knowledge, a study investigating 
circulating miRNAs as diagnostic or prognostic 
biomarkers in LS has so far not been reported. 
Consequently, we decided to address this issue 
in the present study and performed a meta-
analysis of the published miRNA expression 
profiles in LS and screened selected miRNAs as 
diagnostic markers in plasma of LS patients. 
The study led to the discovery of miRNA-155 as 




The present study, approved by the local ethics 
committee (Ref. Nr. EK10/2007), included 13 
patients with MLS, 5 patients with DDLS, 7 
patients with ALT and 10 patients with lipomas 
(Table 1). The 35 patients were admitted for 
treatment to the University Hospital Balgrist, 
University of Zurich, Switzerland, between July 
2011 and October 2014. Upon surgical resec-
tion of the primary tumor, tumor tissue speci-
mens were snap frozen in liquid nitrogen and 
stored at -80°C. The remaining tumor tissue 
was examined by soft tissue pathologists for LS 
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subtype classification according to current 
standard histopathological criteria together 
with immunohistochemical and molecular anal-
yses defined by the WHO guidelines for the 
classification of tumors [23]. Blood was collect-
ed from individual patients 24h before surgery 
in EDTA-coated tubes and plasma was pre-
pared and frozen at -80°C within 2 hours. 
Control blood samples were collected from 20 
healthy age and sex matched volunteers. 
Normal control white fat tissue from upper and 
lower extremities was collected upon written 
consent from 7 healthy subjects.
RNA isolation
RNA was isolated from 200 µL of plasma with 
an miRNeasy Serum/Plasma Kit (Qiagen) 
according to the manufacturer’s instructions. 
Briefly, 1 ml of denaturing lysis reagent was 
added to 200 µL of plasma and kept at room 
temperature for 5 min. 4 µL miRNeasy spike-in 
control miRNA-39 from C. elegans at 1.6×108 
copies/µL was then added as an internal con-
trol for RNA extraction efficiency. RNA extracts 
were stored at -80°C. RNA from freshly frozen 
tumor samples was extracted with an miR-
Neasy Micro Kit (Qiagen) according to the man-
ufacturer’s instructions. Between 20 and 30 
mg of frozen tumor tissues were homogenized 
with TissueLyser LT (Qiagen) and further pro-
cessed according to the manufacturer’s proto-
was done using an miScript SYBR Green PCR 
Kit (Qiagen) according to the manufacturer’s 
instructions. The universal reverse primer pro-
vided in the kit was used in all reactions in com-
bination with the following miScript Primer 
Assays forward primers: Hs_RNU6-2_11, 
Hs_miR-128_1, Hs_miR-93_1, Hs_miR-214- 
_2, Hs_miR-210_1, Hs_miR-16_2, Hs_miR-
221*_1, Hs_miR-21*_1, Hs_miR-593*_1, Hs_
miR-155_2, Hs_miR-181a_2. The PCR reac-
tions were run on an Applied Biosystems Cycler 
(AB) under the following cycling conditions: ini-
tial denaturation at 95°C for 10 min, followed 
by 40 PCR cycles at 95°C for 15 s and at 60°C 
for 1 min. The levels of the investigated miRNAs 
in plasma samples were corrected for miRNA 
extraction efficiency, determined with the 
spiked-in C. elegans miRNA-39, and normalized 
to the levels of miRNA-128 that was determined 
with Norm Finder algorithm to be the least vari-
able and therefore a suitable endogenous con-
trol [24]. In tissue samples, RNU6-2 was con-
sidered as a housekeeping reference and used 
for normalization. Relative expression of miR-
NAs was calculated using 2-ddCt [25].   
Statistical analysis
Statistical analyses were performed using 
GraphPad Prism 5 software (GraphPad 
Software, Inc, USA). Continuous variables are 
shown as mean ± SD. Differences between 
miRNA levels observed in samples of healthy 















Number 20 13 5 7 10
Age (years)
Mean 47.2 45.6 62.6 57.9 51.5 0.067
SD 14.1 13.6 14.2 9.9 10.1
Gender
    Male 13 9 4 3 4 0.402
    Female 7 4 1 4 6
Tumor site
    Lower extremity 12 2 7 4
    Upper extremity 4
    Thorax 1 1 1
    Retroperitoneal 1
    Groin 1
    Back 1
Metastasis 3/13 2/5 0/7 0/10
col. RNA extracts were 
stored at -80°C. RNA con-
centrations and purity 
were analyzed by OD 
260/280 measurements 
in a NanoDrop device 
(Thermo Scientific, USA). 
Reverse transcription 
and qRT-PCR
miRNA was reverse tran-
scribed from 3 µL of indi-
vidual RNA extracts in 
miScript HiSpec Buffer 
with an miScript II RT Kit 
(Qiagen) according to the 
manufacturer’s instruc-
tions. After cDNA synthe-
sis, the samples were 
diluted with 100 µL of 
water and 1 µL was then 
used as substrate for 
qPCR. Quantitative PCR 
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subjects and of LS patients were analyzed for 
statistical significance with the student’s t-test. 
One-way analysis of variance (ANOVA) was used 
when more than two groups were compared 
and differences between groups were subse-
quently determined by the Bonferroni test. The 
correlation of miRNA levels detected in LS 
tumor tissue and in corresponding plasma 
samples was determined by Spearman 
Correlation analysis. The standard formulas 
were used for the calculation of sensitivity and 
specificity. The receiver operating characteris-
tic (ROC) curves were plotted to calculate the 
area under the curve (AUC) in order to assess 
the predictive power of plasma levels of miRNA-
155 for LS. All p values are two sided and 




The characteristics of the patients and of 
healthy individuals included in this study are 
summarized in Table 1. The 35 patients investi-
gated included 10 patients with lipoma, 7 
patients with ALT, 5 patients with DDLS and 13 
with MLS. In addition we analyzed plasma sam-
ples from 20 healthy individuals, who were age 
and sex matched to the patient cohort, and nor-
mal fat tissue from 7 healthy individuals. As 
expected from the higher incidence of DDLS in 
older patients, this group had the highest mean 
age. The group of patients suffering from MLS, 
on the other hand, known to predominantly 
affect younger subjects, exhibited the lowest 
mean age (Table 1). However, the distribution 
of age and sex did not significantly differ 
between the LS subgroups investigated here. In 
the majority of patients, primary tumors were 
located in the extremities, predominantly in the 
legs. Only DDLS showed a wider distribution, 
including patients with tumors located in 
extremities. Patients with lipoma and ALT had 
no metastases, but in the groups of patients 
with malignant tumors, e.g. MLS and DDLS 
23% (3/13) and 40% (2/5), respectively, suf-
fered from metastatic disease. 
Plasma levels of selected miRNAs in liposar-
coma patients and healthy subjects
We performed a meta-analysis of four publical-
ly available microRNA expression profiles for LS 
in order to assemble a list of candidate miRNAs 
to be tested in plasma of LS patients and 
healthy subjects [18, 20-22]. All four of these 
studies investigated miRNAs extracted from 
fresh frozen LS tumor samples, including differ-
ent LS subtypes and normal fat tissue as a con-
trol. Considering that we were interested in 
identifying and analyzing miRNA that was 
released by the tumor cells into the circulation, 
we focused on those miRNAs that were found 
upregulated in any LS subtype when compared 
to benign lipomas and/or normal fat tissue. The 
criterion for selection was more than 2-fold 
higher expressed of miRNA in liposarcomas in 
comparison to normal fat or lipoma. Further 
selection was based upon the presence of 
miRNA in at least 2 of the 4 published studies 
analyzed or that it was confirmed in a validation 
cohort of the same study. Despite the high vari-
ation between miRNA expression profiles in the 
four studies, our meta-analysis provided us 
with the following 9 miRNAs for our study: 
miRNA-16, miRNA-21, miRNA-93, miRNA-155, 
Table 2. Expression levels of selected miRNAs in plasma of patients shown as fold change in compari-
son to expression in plasma of healthy control group





miRNA Up/Down Fold change Up/Down Fold change Up/Down Fold change Up/Down Fold change
miRNA-16 ↑ 1.0 ↑ 1.1 ↑ 1.1 ↑ 1.2
miRNA-21 ↓ 1.8* ↓ 1.1 ↓ 1.2 ↓ 1.6
miRNA-93 ↑ 1.1 ↓ 1.2 ↑ 1.2 ↑ 1.2
miRNA-155 ↓ 1.1 ↑ 3.9* ↓ 1.1 ↑ 1.0
miRNA-181a ↓ 1.6 ↓ 3.7* ↓ 1.2 ↓ 1.3
miRNA-210 ↓ 1.3 ↓ 1.1 ↑ 1.8 ↓ 1.1
miRNA-214 ↓ 1.5 ↑ 1.5 ↓ 1.4 ↓ 1.0
miRNA-593 ↓ 2.3* ↑ 1.1 ↑ 1.1 ↓ 2.2
*-fold change is statistically significant, p < 0.05.
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miRNA-181a, miRNA-210, miRNA-214, miRNA-
221, and miRNA-593. All of these miRNAs were 
detectable by qRT-PCR in the plasma samples 
investigated here except for miRNA-221 that 
remained undetectable. The fold-changes (up 
or down) in the levels of the selected miRNAs in 
the plasma of LS patients compared to healthy 
controls are summarized in the Table 2. For the 
vast majority of the miRNAs analyzed, only 
minor differences were observed between 
plasma levels in the different LS subtypes and 
in the healthy controls. However, the mean lev-
els of circulating miRNA-21 and miRNA-593 in 
MLS were significantly (p < 0.05) decreased 
compared to control. In addition, plasma levels 
of miRNA181a in patients with DDLS were 3.7-
times lower than in control subjects (p < 0.05). 
In contrast and most interestingly, patients 
with DDLS exhibited significantly (p < 0.05; 3.9-
times) higher levels of miRNA-155 in the circu-
lation than control subjects; importantly, all 
other subgroups of LS patients had plasma lev-
els of miRNA-155 indistinguishable from those 
detected in normal individuals. Consequently, 
we decided to further investigate circulating 
miRNA-155 as a novel diagnostic marker in 
DDLS.
Elevated circulating miRNA-155, a specific 
non-invasive indicator for dedifferentiated 
liposarcoma, correlates with an upregulated 
expression in tumor tissue
The results illustrated in Figure 1B demon-
strate a significantly (p < 0.05) higher expres-
sion of miRNA-155 in DDLS tumor tissue than 
in normal fat tissue. Moreover and in perfect 
agreement with the findings described for the 
Figure 1. The levels of miRNA-155 in the circulation of liposarcoma patients correlate with the levels in correspond-
ing tumor tissue extracts. A. Median (± SD) levels of miRNA-155 in plasma of indicated liposarcoma patients and 
healthy control subjects measured by qRT-PCR and normalized to miRNA-126 levels, plotted as % of maximum 
value. B. Median (± SD) levels of miRNA-155 measured by qRT-PCR in extracts of indicated liposarcoma tumor 
tissues and normal fat samples, normalized to RNU6.2, plotted as % of maximum value. C. Spearman correlation 
of miRNA-155 levels detected in plasma and in corresponding tumor tissue extracts of patients with adipocytic 
tumors, r-correlation coefficient. D. Spearman correlation of miRNA-155 levels detected in plasma and tumor tis-
sue extracts of patients with malignant liposarcoma (CON-healthy subjects, NF-fat tissue from healthy subjects, 
MLS-myxoid liposarcoma, DDLS-dedifferentiated liposarcoma, ALT-atypic lipomatous tumors, L-lipomas; *-p < 0.05, 
**-p < 0.001).
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plasma samples, the levels of miRNA-155 
expression in DDLS tumors were significantly 
higher than those detected in any other LS 
tumor subtype (Figure 1A, 1B). Of most impor-
tant diagnostic and even prognostic relevance 
are the significantly elevated plasma and tumor 
tissue miRNA-155 levels in DDLS compared to 
those found in patients with ALT, since DDLS 
develops from ALT. A Spearman Correlation 
analysis of the plasma and tumor tissue levels 
measured in individual patients of all LS sub-
types revealed a statistically significant (r=0.41, 
p=0.02) correlation between the two parame-
ters (Figure 1C). This correlation was even 
stronger (r=0.51, p=0.01) when only malignant 
lipomatous tumors were included in the analy-
sis (Figure 1D). 
Diagnostic accuracy of plasma miRNA-155 in 
liposarcoma
We performed a ROC curve analysis to assess 
the potential usefulness of plasma miRNA-155 
levels as a noninvasive diagnostic marker for 
LS. As shown in Figure 2A, an analysis designed 
to distinguish patients with DDLS from healthy 
controls yielded an AUC value of 0.910 (95% CI, 
0.783-1.037). We further explored whether 
plasma miRNA-155 can distinguish between 
DDLS and other LS subtypes. The analysis per-
formed with plasma miRNA-155 levels of 
patients with DDLS or ALT revealed an AUC of 
0.914 (95% CI, 0.751-1.077) (Figure 2B). 
miRNA-155 proved to be also useful to distin-
guish DDLS from lipomas (AUC 0.860 (95% CI, 
0.659-1.061)) (Figure 2C) and from MLS (AUC 
0.923 (95% CI, 0.798-1.048)) (Figure 2D). 
Taken together, these results indicate that the 
levels of circulating miRNA-155 in LS patients 
are a useful noninvasive biomarker with high 
diagnostic power for DDLS.
Discussion
In many tumor types, miRNA expression corre-
lates with various biological and clinical proper-
ties [16]. Sarcomas are no exception, since 
miRNA profiling was shown to be useful for 
tumor subtype classification and a strong cor-
relation with aggressiveness, response to ther-
apy and tumor differentiation was observed 
[17, 18]. It is also well known that miRNAs are 
Figure 2. Diagnostic accuracy of miRNA-155 levels detected in plasma of liposarcoma patients. The ROC curve plot-
ted to distinguish DDLS patients from healthy subjects (A), from ALT patients (B), from lipoma patients (C) and from 
MLS patients (D). AUC-area under the curve.
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actively secreted by the tumor cells into the cir-
culation and can therefore be used as circulat-
ing tumor biomarkers [26]. Based on these 
observations, we investigated such circulating 
miRNAs as biomarkers in LS. 
Concerning LS, there exist four studies on 
miRNA profiling in tumor tissue [18, 20-22]. 
These reports describe a differential analysis 
between normal fat and LS subtypes that 
revealed specific miRNA signatures for each LS 
subtype. Following these studies only few miR-
NAs were studied in depth for their biological 
role in LS and a secondary validation of their 
expression was rarely included. In the study by 
Gits et al. the authors observed distinct miRNA 
expression patterns for each LS subtype. 
Furthermore, miRNA-145 and miRNA-451, 
which were found down-regulated in DDLS 
compared to normal fat, were validated as 
tumor suppressors [20]. This work also con-
firmed previous findings with miRNA-143 as a 
tumor suppressor miRNA in LS [22]. Zhang et 
al. focused on differential miRNA expression in 
DDLS/ALT and normal fat. This study revealed 4 
up-regulated and 31 down-regulated miRNAs in 
diseased compared to normal tissue. Among 
these they validated miRNA-10, miRNA-126 
and miRNA-155 in subsequent experiments. 
Strikingly, there was little overlap between the 
four studies investigating miRNA expression 
profiles in LS. When we only compared up-regu-
lated miRNAs in DDLS over normal fat in the 
four published expression profiles, we found 
not a single miRNA appearing in all four lists. 
Nevertheless, we selected 9 miRNAs that were 
found significantly upregulated more than 
2-fold in LS compared to normal fat in at least 
two of the four studies, for further evaluation in 
plasma of our LS patient cohort. We focused 
only on upregulated miRNAs in our meta-analy-
sis since we assumed a higher probability for 
the release of up- rather than down-regulated 
miRNA from tumor tissue into the circulation. 
Interestingly, we were able to detect all but one 
miRNA (miRNA-221) in plasma of LS patients 
as summarized in Table 2. Out of 8 miRNAs, 
only three miRNAs showed a significantly differ-
ent change in plasma levels of patients with a 
particular LS subtype compared to the levels 
detected in patients with any other LS sub-
types. However, in the case of miRNA-21 and 
miRNA-181a we detected decreased levels in 
MLS and DDLS patients respectively, in com-
parison to healthy control subjects. This finding 
contrasts with an upregulated expression of 
these miRNAs in LS tumors reported by Gits et 
al. [20]. In the light of this discrepancy, we 
decided to analyze the expression of miRNA-21 
and miRNA-181a in LS tumor samples. We did 
not observe any LS subtype related change in 
expression in tumor tissue that would correlate 
with the levels found in plasma (data not 
shown). The discovery of an almost 4-fold high-
er expression of miRNA-155 in plasma of DDLS 
patients compared to healthy individuals 
prompted us to further focus on this miRNA. 
Nevertheless, it is striking that only one miRNA 
showed significant increase in plasma out of 9 
we expected from their elevation in tumor tis-
sue, which further emphasizes that presence of 
tumor originating miRNAs in the circulation is a 
result of active excretion of only some miRNAs 
thus not always reflecting the expression in 
tumor cells.
It has recently been shown by Zhang et al. that 
miRNA-155 is overexpressed in DDLS tumors 
[21]. Furthermore, they were able to show a 
DDLS tumor growth driving activity of miRNA-
155 that targets Casein kinase 1α and thereby 
interferes with the Wnt/b-catenin pathway [21]. 
A very recent study by Vincenzi et al. confirmed 
miRNA-155 overexpression in DDLS tumors 
[27]. Since miRNA-155 was shown to play an 
important role in DDLS tumors, we hypothe-
sized that tumor and plasma levels of miRNA-
155 may correlate in DDLS patients. The 
results of the present study demonstrate that 
the plasma levels of miRNA-155 measured in 
individual LS patients correlated significantly 
with the levels detected in corresponding tumor 
extracts, providing strong evidence for the pos-
tulated tumor origin of elevated circulating 
miRNA-155 in LS patients including those with 
DDLS.
ROC curve analysis confirmed that increased 
levels of miRNA-155 in plasma are a reliable 
non-invasive parameter to distinguish DDLS 
patients from both healthy controls, as well as 
patients with other LS subtypes including 
benign lipomas. Even more important in view of 
the difficult and laborious diagnostic proce-
dures needed for a meaningful differential 
diagnosis of ALT and DDLS is the fact that 
miRNA-155 can be used as a noninvasive bio-
marker that allows to distinguish ALT and DDLS 
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patients with high accuracy reflected by a sen-
sitivity of 80% and a specificity of 80% 
(AUC=0.914, 95% CI, 0.751-1.077). The diag-
nostic power of miRNA-155 is of limited impor-
tance in distinguishing easy-to-diagnose cases 
due to for example classical localization of 
DDLS in retroperitoneum. However, the rele-
vance of miRNA-155 as a marker is as an addi-
tional, non-invasive marker in difficult cases 
such as DDLS located in extremities and mis-
leading histology finding based on lipogenic 
component of DDLS tumor. Exactly those kinds 
of cases have been included in this study and 
they provide proof of principle. 
However, miRNA-155 was shown to be also 
overexpressed in several other cancers includ-
ing thyroid carcinoma, breast cancer, colon 
cancer, cervical cancer, pancreatic ductal ade-
nocarcinoma, and lung cancer, and it was also 
found to be an indicator for a poor prognosis in 
all these cancers [28]. Interestingly, in lung can-
cer and in breast cancer in particular, circulat-
ing miRNA-155 was shown to be a powerful 
diagnostic marker with a sensitivity and speci-
ficity similar to that observed in the present 
study [26, 28]. Thus, these and our own find-
ings show that miRNA-155 alone is not a unique 
circulating biomarker for the diagnosis of DDLS 
or any other type of cancer, but deserves fur-
ther validation as a first valuable, circulating 
biomarker in LS diagnostics to differentiate 
between DDLS and ALT and to monitor DDLS 
treatment.
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